GUFICBIO

Gufic Biosciences Limited

Pharmaceuticals company with API and finished-dosage manufacturing

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

gufic.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹404.50
Market cap
4,066 Cr
Stock P/E
55.3
P/B
6.11
Dividend yield
0.0%
ROE (FY26)
9.7%
ROCE (FY26)
11.7%
Operating margin (FY26)
12.8%
Debt / equity (FY26)
0.58
OCF / EBITDA (FY26)
29.7%
OCF / EBITDA (3Y)
37.1%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Gufic Biosciences makes injectable medicines, with freeze-dried (lyophilised) products as its core business, and sells them under its own brands in India and abroad while also manufacturing for other pharmaceutical companies.

Company snapshot

65thBy market cap

Ranked among 119 companies in Pharmaceuticals.

Segment mix

Reportable segments as of 2018-03-31 (Standalone). Revenue share = segment revenue ÷ total revenue.

Largest segment: 93.8% of revenue

SegmentRevenue shareRevenuePBTAssets
Bulk Drug
6.2%
19 Cr3 Cr—
Consumer—0 Cr0 Cr—
Pharma
93.8%
285 Cr51 Cr—

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales215 Cr202 Cr195 Cr203 Cr204 Cr208 Cr205 Cr224 Cr237 Cr231 Cr252 Cr261 Cr
Operating expenses (approx.)176 Cr165 Cr161 Cr167 Cr166 Cr174 Cr179 Cr190 Cr199 Cr198 Cr205 Cr214 Cr
EBITDA39 Cr36 Cr34 Cr36 Cr39 Cr34 Cr26 Cr33 Cr38 Cr33 Cr47 Cr47 Cr
OPM %18.3%18.1%17.6%17.6%18.9%16.3%12.9%14.9%16.0%14.3%18.7%17.9%
Other income0.33 Cr0.42 Cr0.88 Cr1 Cr0.11 Cr2 Cr0.39 Cr0.93 Cr2 Cr0.79 Cr-1 Cr0.46 Cr
Interest4 Cr3 Cr4 Cr5 Cr5 Cr5 Cr8 Cr9 Cr10 Cr8 Cr9 Cr9 Cr
Depreciation4 Cr4 Cr4 Cr4 Cr4 Cr5 Cr8 Cr8 Cr8 Cr8 Cr8 Cr8 Cr
Profit before tax31 Cr30 Cr27 Cr28 Cr29 Cr26 Cr11 Cr17 Cr23 Cr18 Cr29 Cr30 Cr
Tax %25.0%24.7%26.1%25.8%25.6%26.5%26.7%24.3%25.6%29.9%24.4%25.7%
Net profit23 Cr22 Cr20 Cr21 Cr22 Cr19 Cr8 Cr13 Cr17 Cr12 Cr22 Cr22 Cr
EPS (₹)₹2.39₹2.23₹2.00₹2.08₹2.17₹1.93₹0.77₹1.30₹1.68₹1.24₹2.18₹2.22

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2024Mar 2025Mar 2026TTM
Sales807 Cr820 Cr944 CrSign in free for the trailing twelve months
Operating expenses (approx.)661 Cr685 Cr793 CrSign in free for the trailing twelve months
EBITDA146 Cr135 Cr151 CrSign in free for the trailing twelve months
OPM %18.1%16.4%16.0%Sign in free for the trailing twelve months
Other income2 Cr4 Cr3 CrSign in free for the trailing twelve months
Interest15 Cr23 Cr37 CrSign in free for the trailing twelve months
Depreciation17 Cr21 Cr31 CrSign in free for the trailing twelve months
Profit before tax116 Cr94 Cr87 CrSign in free for the trailing twelve months
Tax %25.5%26.0%25.8%Sign in free for the trailing twelve months
Net profit86 Cr70 Cr64 CrSign in free for the trailing twelve months
EPS (₹)₹8.74₹6.95₹6.40Sign in free for the trailing twelve months
Dividend payout %1.1%1.4%1.6%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2024Mar 2025Mar 2026
Equity capital10 Cr10 Cr10 Cr
Reserves523 Cr591 Cr655 Cr
Borrowings317 Cr310 Cr385 Cr
Other liabilities243 Cr258 Cr292 Cr
Total liabilities1,093 Cr1,169 Cr1,342 Cr
Fixed assets (net)153 Cr500 Cr485 Cr
CWIP307 Cr22 Cr22 Cr
Investments2 Cr2 Cr2 Cr
Loans & advances0.37 Cr0.32 Cr0.66 Cr
Inventories200 Cr217 Cr324 Cr
Trade receivables330 Cr315 Cr297 Cr
Cash & bank1 Cr16 Cr62 Cr
Other assets98 Cr99 Cr149 Cr
Total assets1,093 Cr1,169 Cr1,342 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2024Mar 2025Mar 2026
Cash from operating activity-7 Cr123 Cr45 Cr
Cash from investing-102 Cr-71 Cr-31 Cr
Cash from financing82 Cr-37 Cr32 Cr
Net cash flow-27 Cr15 Cr46 Cr
Free cash flow (OCF − Capex)-120 Cr47 Cr14 Cr

Ratios

MetricMar 2024Mar 2025Mar 2026
ROCE %15.4%12.9%11.7%
ROE %16.2%11.6%9.7%
Debtor days149140115
Inventory days214229278
Days payable178168170
Cash conversion cycle186201222
OCF / EBITDA %-5.1%91.0%29.7%
OCF / EBITDA % (3 years)——37.1%
Debt / equity0.600.520.58
Current ratio1.611.611.55
Net debt / EBITDA2.172.192.13